Geron Q1 Earnings Call Highlights

1 day ago 5

MarketBeat

Wed, May 6, 2026 astatine 8:07 AM CDT 8 min read

Geron logo

Key Points

Q1 nett gross of $61.8 million (up 31% YoY) and Geron reiterated full‑year Rytelo guidance of $220–240 million, noting maturation is weighted to H2 2026 portion gross‑to‑net roseate to 21% (expected low‑mid 20s for the year) owed to wider 340B usage and expanded GPO contracting.
U.S. commercialized execution is scaling — Rytelo present reaches astir 1,450 prescribing accounts with 6% QoQ request growth; the institution is prioritizing the ~8,000‑patient second‑line lower‑risk MDS marketplace and imetelstat’s inclusion successful the NCCN chemotherapy bid template positions it arsenic the preferred second‑line option.
Pipeline and planetary plans: the afloat enrolled Phase 3 IMpactMF proceedings is expected to deed its interim overall‑survival lawsuit trigger successful H2 2026 (final investigation basal lawsuit H2 2028), Geron is evaluating European commercialization pathways with an update planned earlier year‑end, and it ended Q1 with astir $341 cardinal successful currency aft little operating expenses.
Interested successful Geron Corporation? Here are 5 stocks we similar better.

Geron Corporation: FDA Approval Fuels Stock Price Surge

Geron (NASDAQ:GERN) reported first-quarter 2026 nett gross of $61.8 million, up 31% year-over-year and 8% quarter-over-quarter, arsenic the institution continued to standard commercialization of Rytelo successful the U.S. Management reiterated full-year 2026 guidance and outlined ongoing enactment to measure a European commercialization approach, portion besides previewing expected milestones for its Phase 3 myelofibrosis program.

Rytelo gross maturation and 2026 guidance reiterated

Chief Executive Officer Harout Semerjian said Geron made advancement connected its 2026 strategical priorities successful the 4th by increasing Rytelo done “focused commercialized execution” and advancing its European strategy “while maintaining our fiscal discipline.”

→ Roblox Stock Slides to New Low arsenic Safety Changes Weigh connected Outlook

Geron Stock Doubles After Imetelstat Receives FDA Panel Approval

Chief Financial Officer Michelle Robertson said full nett gross for the 3 months ended March 31, 2026 was $61.8 million, compared with $39.6 cardinal successful the prior-year period. Geron reiterated its 2026 nett gross guidance for Rytelo of $220 cardinal to $240 million, with Robertson noting that “a greater information of growth” is anticipated successful the backmost fractional of the year.

Robertson besides highlighted a displacement successful gross-to-net dynamics arsenic measurement increased. Gross-to-net reductions roseate to 21% successful the 4th from 13% a twelvemonth earlier, driven by “wider 340B utilization and expanded GPO contracting.” For the remainder of 2026, she said the institution expects gross-to-net to beryllium successful the “low to mid 20s.”

Read Entire Article